Measurable residual disease (MRD) has become a key biomarker in the field of multiple myeloma (MM), and the sensitivity of MRD testing has increased in recent years. MRD can indicate the depth of response to treatment as well as patient outcomes, leading to suggestions of using MRD status to guide the treatment of patients with myeloma. 

In this podcast, you will hear from Meral Beksac, MD, Ankara University, Ankara, Turkey, Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, and Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, who discuss the exciting potential applications of MRD in multiple myeloma and share insights from recent clinical trials.